Hepatocellular carcinoma in olmsted county, Minnesota, 1976-2008
- PMID: 22212963
- PMCID: PMC3538386
- DOI: 10.1016/j.mayocp.2011.07.001
Hepatocellular carcinoma in olmsted county, Minnesota, 1976-2008
Abstract
Objective: To analyze longitudinal trends in the incidence, etiology, and treatment of hepatocellular carcinoma (HCC) in community residents in Olmsted County, Minnesota, and their survival.
Patients and methods: Olmsted County residents 20 years or older with HCC newly diagnosed from January 1, 1976, through December 31, 2008, were identified using a community-wide medical record linkage system (Rochester Epidemiology Project). The incidence rate of HCC was calculated by age and sex according to the 2000 US Census population. Temporal trends of HCC etiology, treatment, and patient survival were assessed.
Results: The age- and sex-adjusted incidence rate for HCC in Olmsted County was 3.5 per 100,000 person-years for the first era (1976-1990), 3.8 per 100,000 for the second era (1991-2000), and 6.9 per 100,000 for the third era (2001-2008). Alcohol use was the most common risk factor in the first and second eras and chronic hepatitis C virus in the third. The proportion attributed to nonalcoholic fatty liver disease was small (5/47 [10.6%] in the third era). Because the proportion of patients receiving curative treatment increased over time, survival also improved, with a median survival time of 3, 6, and 9 months in the first, second, and third eras, respectively (P=.01).
Conclusion: In this midwestern US community, the incidence of HCC has increased, primarily due to hepatitis C virus. Although there was a demonstrable improvement in the outcome of HCC in community residents over time, the overall prognosis remains poor.
Copyright © 2012 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.
Figures


Similar articles
-
Recent Trends in the Epidemiology of Hepatocellular Carcinoma in Olmsted County, Minnesota: A US Population-based Study.J Clin Gastroenterol. 2017 Sep;51(8):742-748. doi: 10.1097/MCG.0000000000000810. J Clin Gastroenterol. 2017. PMID: 28445235 Free PMC article.
-
Factors that affect risk for hepatocellular carcinoma and effects of surveillance.Clin Gastroenterol Hepatol. 2011 Jul;9(7):617-23.e1. doi: 10.1016/j.cgh.2011.03.027. Epub 2011 Apr 1. Clin Gastroenterol Hepatol. 2011. PMID: 21459158
-
Biliary tract cancers in Olmsted County, Minnesota, 1976-2008.Am J Gastroenterol. 2012 Aug;107(8):1256-62. doi: 10.1038/ajg.2012.173. Epub 2012 Jul 3. Am J Gastroenterol. 2012. PMID: 22751468 Free PMC article.
-
Hepatocellular carcinoma: recent trends in the United States.Gastroenterology. 2004 Nov;127(5 Suppl 1):S27-34. doi: 10.1053/j.gastro.2004.09.013. Gastroenterology. 2004. PMID: 15508094 Review.
-
From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world.World J Gastroenterol. 2017 Aug 7;23(29):5282-5294. doi: 10.3748/wjg.v23.i29.5282. World J Gastroenterol. 2017. PMID: 28839428 Free PMC article. Review.
Cited by
-
Hepatocellular Carcinoma Screening and Nonalcoholic Fatty Liver Disease: How is it Different?J Clin Exp Hepatol. 2020 Sep-Oct;10(5):518-524. doi: 10.1016/j.jceh.2020.04.004. Epub 2020 Apr 18. J Clin Exp Hepatol. 2020. PMID: 33029058 Free PMC article. Review.
-
Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link.World J Gastroenterol. 2022 Jan 21;28(3):310-331. doi: 10.3748/wjg.v28.i3.310. World J Gastroenterol. 2022. PMID: 35110952 Free PMC article. Review.
-
NAFLD, NASH and liver cancer.Nat Rev Gastroenterol Hepatol. 2013 Nov;10(11):656-65. doi: 10.1038/nrgastro.2013.183. Epub 2013 Oct 1. Nat Rev Gastroenterol Hepatol. 2013. PMID: 24080776 Review.
-
Recurrent hepatocellular carcinoma: it's the virus!J Clin Oncol. 2013 Oct 10;31(29):3621-2. doi: 10.1200/JCO.2013.51.8381. Epub 2013 Sep 3. J Clin Oncol. 2013. PMID: 24002518 Free PMC article. No abstract available.
-
Chaihu-Shugan-San Decoction Modulates Intestinal Microbe Dysbiosis and Alleviates Chronic Metabolic Inflammation in NAFLD Rats via the NLRP3 Inflammasome Pathway.Evid Based Complement Alternat Med. 2018 Jul 11;2018:9390786. doi: 10.1155/2018/9390786. eCollection 2018. Evid Based Complement Alternat Med. 2018. PMID: 30105078 Free PMC article.
References
-
- Kim W.R., Gores G.J., Benson J.T., Therneau T.M., Melton L.J., III Mortality and hospital utilization for hepatocellular carcinoma in the United States. Gastroenterology. 2005;129(2):486–493. - PubMed
-
- Perz J.F., Armstrong G.L., Farrington L.A., Hutin Y.J., Bell B.P. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529–538. - PubMed
-
- Bosch F.X., Ribes J., Diaz M., Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127(5 Suppl 1):S5–S16. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical